Abstract
p73, the first homologue of the tumour suppressor protein p53, was recently discovered on chromosome 1p36 and has been shown to induce apoptosis in a p53-like manner. The present study was performed with the aim of investigating the expression of p53, its new homologue p73 and the occurrence of apoptosis in cholangiocellular carcinoma. Protein levels of p73 were examined in 41 patients with curatively (R0-) resected cholangiocellular carcinomas with an antiserum, raised against a peptide in the N-terminal domain of p73. The incidence of mutations in the p53 gene was analysed by direct sequencing and also immunohistochemically. Apoptotic cell death was assessed using in-situ end-labelling (ISEL) technique in combination with morphological criteria. The results obtained were correlated with patient survival. Immunostaining of p73 protein was detected in 17/41 carcinomas examined (41%). The immunoreactivity was confined to the cell nucleus. In 15/41 patients (37%), mutations of the p53 gene were observed. Eleven out of these 15 patients stained also positive for p73. In contrast, out of 26 patients without any detectable p53 mutation, only six exhibited p73 immunostaining. We failed to observe a correlation between p73 expression or p53 and apoptosis within a given tumour. Survival analysis including the parameters stage and grade of disease, p73 and p53, and also apoptosis, showed that tumour stage and grade as well as p53 and p73 were significantly related to prognosis. In Cox regression survival analysis, however, only extent of primary tumour and lymph node status had an independent prognostic impact. Our results with a high prevalence of p73 within tumours harbouring mutated p53 gene suggest that p73 could compensate for p53 function. We failed to establish p73 or p53 as independent prognostic factors in cholangiocellular carcinoma of the liver. © 1999 Cancer Research Campaign
Keywords: cholangiocellular carcinoma, p73, p53, apoptosis, prognosis
Full Text
The Full Text of this article is available as a PDF (254.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Clurman B., Groudine M. Tumour-suppressor genes. Killer in search of a motive? Nature. 1997 Sep 11;389(6647):122–123. doi: 10.1038/38116. [DOI] [PubMed] [Google Scholar]
- Harris C. C. The 1995 Walter Hubert Lecture--molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. Br J Cancer. 1996 Feb;73(3):261–269. doi: 10.1038/bjc.1996.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hui A. M., Kanai Y., Sakamoto M., Tsuda H., Hirohashi S. Reduced p21(WAF1/CIP1) expression and p53 mutation in hepatocellular carcinomas. Hepatology. 1997 Mar;25(3):575–579. doi: 10.1002/hep.510250314. [DOI] [PubMed] [Google Scholar]
- Jost C. A., Marin M. C., Kaelin W. G., Jr p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature. 1997 Sep 11;389(6647):191–194. doi: 10.1038/38298. [DOI] [PubMed] [Google Scholar]
- Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J. C., Valent A., Minty A., Chalon P., Lelias J. M., Dumont X. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997 Aug 22;90(4):809–819. doi: 10.1016/s0092-8674(00)80540-1. [DOI] [PubMed] [Google Scholar]
- Mai M., Yokomizo A., Qian C., Yang P., Tindall D. J., Smith D. I., Liu W. Activation of p73 silent allele in lung cancer. Cancer Res. 1998 Jun 1;58(11):2347–2349. [PubMed] [Google Scholar]
- Nomoto S., Haruki N., Kondo M., Konishi H., Takahashi T., Takahashi T., Takahashi T. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res. 1998 Apr 1;58(7):1380–1383. [PubMed] [Google Scholar]
- Ohashi K., Nakajima Y., Kanehiro H., Tsutsumi M., Taki J., Aomatsu Y., Yoshimura A., Ko S., Kin T., Yagura K. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology. 1995 Nov;109(5):1612–1617. doi: 10.1016/0016-5085(95)90650-9. [DOI] [PubMed] [Google Scholar]
- Orita M., Suzuki Y., Sekiya T., Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 1989 Nov;5(4):874–879. doi: 10.1016/0888-7543(89)90129-8. [DOI] [PubMed] [Google Scholar]
- Sun X. F., Carstensen J. M., Zhang H., Stål O., Wingren S., Hatschek T., Nordenskjöld B. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet. 1992 Dec 5;340(8832):1369–1373. doi: 10.1016/0140-6736(92)92558-w. [DOI] [PubMed] [Google Scholar]
- Takahashi H., Ichimiya S., Nimura Y., Watanabe M., Furusato M., Wakui S., Yatani R., Aizawa S., Nakagawara A. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res. 1998 May 15;58(10):2076–2077. [PubMed] [Google Scholar]
- Tannapfel A., Hahn H. A., Katalinic A., Fietkau R. J., Kühn R., Wittekind C. W. Prognostic value of ploidy and proliferation markers in renal cell carcinoma. Cancer. 1996 Jan 1;77(1):164–171. doi: 10.1002/(SICI)1097-0142(19960101)77:1<164::AID-CNCR27>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
- Tannapfel A., Nüsslein S., Fietkau R., Katalinic A., Köckerling F., Wittekind C. Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):585–591. doi: 10.1016/s0360-3016(98)00076-5. [DOI] [PubMed] [Google Scholar]
- Uhlman D. L., Nguyen P. L., Manivel J. C., Aeppli D., Resnick J. M., Fraley E. E., Zhang G., Niehans G. A. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst. 1994 Oct 5;86(19):1470–1475. doi: 10.1093/jnci/86.19.1470. [DOI] [PubMed] [Google Scholar]